First Time Loading...

Omnicell Inc
NASDAQ:OMCL

Watchlist Manager
Omnicell Inc Logo
Omnicell Inc
NASDAQ:OMCL
Watchlist
Price: 29.98 USD -0.5% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one OMCL stock under the Base Case scenario is 65.99 USD. Compared to the current market price of 29.98 USD, Omnicell Inc is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OMCL Relative Value
Base Case
65.99 USD
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.2
P/S
P/S
Price to Sales
1.2
vs History
93
vs Industry
64
Median 3Y
2.7
Median 5Y
3.6
Industry
2.4
Forward
1.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
74.5
Median 5Y
67.1
Industry
23.4
Forward
27.3
More Details
7.5
P/OCF
P/OCF
Price to OCF
7.5
vs History
90
vs Industry
42
Median 3Y
27.4
Median 5Y
26.3
Industry
15.5
More Details
11.2
P/FCFE
P/FCFE
Price to FCFE
11.2
vs History
42
vs Industry
32
Median 3Y
21.9
Median 5Y
10.2
Industry
23.2
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
93
vs Industry
61
Median 3Y
3
Median 5Y
4
Industry
2.3
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
93
vs Industry
63
Median 3Y
2.8
Median 5Y
3.7
Industry
2.5
Forward
1.3
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
93
vs Industry
61
Median 3Y
6.3
Median 5Y
7.6
Industry
5.3
More Details
21.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.2
vs History
88
vs Industry
16
Median 3Y
34.9
Median 5Y
30.4
Industry
12.6
Forward
14.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
3
Median 3Y
68.5
Median 5Y
57.8
Industry
17.2
Forward
35
More Details
8
EV/OCF
EV/OCF
Enterprise Value to OCF
8
vs History
90
vs Industry
42
Median 3Y
27.4
Median 5Y
26.3
Industry
15.3
More Details
11.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11.5
vs History
85
vs Industry
33
Median 3Y
34.5
Median 5Y
35.9
Industry
19.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
93
vs Industry
64
Median 3Y
2
Median 5Y
2.8
Industry
2
More Details

Multiples Across Competitors

OMCL Competitors Multiples
Omnicell Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Omnicell Inc
NASDAQ:OMCL
1.4B USD 1.2 -67 21.2 -74.7
US
Veeva Systems Inc
NYSE:VEEV
32.8B USD 13.9 62.3 62.2 66.9
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
AU
Pro Medicus Ltd
ASX:PME
11.8B AUD 80.8 169.5 116.5 116.5
US
Inspire Medical Systems Inc
NYSE:INSP
7.4B USD 11.9 -350.7 -185.9 -172.8
JP
M3 Inc
TSE:2413
1.2T JPY 4.8 24.9 12.5 14.1
US
Doximity Inc
NYSE:DOCS
4.6B USD 9.8 33.3 22.3 23.8
SE
Sectra AB
STO:SECT B
42.6B SEK 26.1 100.4 -66.6 -66.6
US
Evolent Health Inc
NYSE:EVH
3.1B USD 1.6 -21.8 25.7 274
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.9B USD 3.9 -332 35.4 -115.7
P/E Multiple
Earnings Growth
US
Omnicell Inc
NASDAQ:OMCL
Average P/E: 72.9
Negative Multiple: -67 		N/A
US
Veeva Systems Inc
NYSE:VEEV
62.3
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
AU
Pro Medicus Ltd
ASX:PME
169.5
119%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -350.7 N/A
JP
M3 Inc
TSE:2413
24.9
26%
US
Doximity Inc
NYSE:DOCS
33.3
79%
SE
Sectra AB
STO:SECT B
100.4
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -21.8 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -332 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Omnicell Inc
NASDAQ:OMCL
Average EV/EBITDA: 36.9
21.2
90%
US
Veeva Systems Inc
NYSE:VEEV
62.2
211%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
AU
Pro Medicus Ltd
ASX:PME
116.5
124%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -185.9 N/A
JP
M3 Inc
TSE:2413
12.5
24%
US
Doximity Inc
NYSE:DOCS
22.3
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.6 N/A
US
Evolent Health Inc
NYSE:EVH
25.7
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
35.4
305%
EV/EBIT Multiple
EBIT Growth
US
Omnicell Inc
NASDAQ:OMCL
Average EV/EBIT: 92.2
Negative Multiple: -74.7 		N/A
US
Veeva Systems Inc
NYSE:VEEV
66.9
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
AU
Pro Medicus Ltd
ASX:PME
116.5
110%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -172.8 N/A
JP
M3 Inc
TSE:2413
14.1
N/A
US
Doximity Inc
NYSE:DOCS
23.8
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.6 N/A
US
Evolent Health Inc
NYSE:EVH
274
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -115.7 N/A

See Also

Summary
OMCL intrinsic value, competitors valuation, and company profile.
DCF Valuation
OMCL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OMCL stock valuation using valuation multiples.
Wall Street Estimates
OMCL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OMCL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.